189
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Development of a Rapid and Reliable Single-Tube Multiplex Real-Time PCR Method for HLA-A*24:02 Genotyping

, , , , , , & show all
Pages 803-812 | Received 10 Apr 2019, Accepted 24 May 2019, Published online: 01 Aug 2019

Reference

  • Mockenhaupt M , MessenheimerJ , TennisP , SchlingmannJ. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology64(7), 1134–1138 (2005).
  • Arif H , BuchsbaumR , WeintraubDet al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology68(20), 1701–1709 (2007).
  • Yang CY , DaoRL , LeeTJet al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology77(23), 2025–2033 (2011).
  • Wang YH , ChenCB , TassaneeyakulWet al. The medication risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label. Clin. Pharmacol. Therap.105(1), 112–120 (2019).
  • Mockenhaupt M , ViboudC , DunantAet al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Investig. Dermatol.128(1), 35–44 (2008).
  • Roujeau JC , KellyJP , NaldiLet al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. New Engl. J. Med.333(24), 1600–1607 (1995).
  • Fricke-Galindo I , ALL , Jung-CookH , Lopez-LopezM. Carbamazepine adverse drug reactions. Exp. Rev. Clin. Pharmacol.11(7), 705–718 (2018).
  • Genin E , SchumacherM , RoujeauJCet al. Genome-wide association study of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J. Rare Dis.6, 52 (2011).
  • Roujeau JC , SternRS. Severe adverse cutaneous reactions to drugs. New Engl. J. Med.331(19), 1272–1285 (1994).
  • Chave TA , MortimerNJ , SladdenMJ , HallAP , HutchinsonPE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol.153(2), 241–253 (2005).
  • Chung WH , HungSI. Genetic markers and danger signals in Stevens–Johnson syndrome and toxic epidermal necrolysis. Allergol. Int.59(4), 325–332 (2010).
  • Su SC , HungSI , FanWL , DaoRL , ChungWH. Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation. Int. J. Mol. Sci.17(11), (2016).
  • Dean L . Carbamazepine therapy and HLA genotype. In: Medical Genetics Summaries. PrattV, McLeodH, RubinsteinW, DeanL, KattmanB, MalheiroA ( Eds). National Center for Biotechnology Information (US), Bethesda, MD, USA, 101–128 (2012).
  • Grover S , KukretiR. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet. Genomics24(2), 94–112 (2014).
  • Sousa-Pinto B , CorreiaC , GomesLet al. HLA and delayed drug-induced hypersensitivity. Int. Arch. allergy Immunol.170(3), 163–179 (2016).
  • Bloch KM , SillsGJ , PirmohamedM , AlfirevicA. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics15(6), 857–868 (2014).
  • Ramirez E , BellonT , TongHYet al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol. Res.115, 168–178 (2017).
  • Wang Q , ZhouJQ , ZhouLMet al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure20(6), 446–448 (2011).
  • Tassaneeyakul W , TiamkaoS , JantararoungtongTet al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia51(5), 926–930 (2010).
  • Chung WH , HungSI , HongHSet al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature428(6982), 486 (2004).
  • Hung SI , ChungWH , JeeSHet al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics16(4), 297–306 (2006).
  • Hung SI , ChungWH , ChenYT. HLA-B genotyping to detect carbamazepine-induced Stevens–Johnson syndrome: implications for personalizing medicine. Personal. Med.2(3), 225–237 (2005).
  • Tangamornsuksan W , ChaiyakunaprukN , SomkruaR , LohitnavyM , TassaneeyakulW. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol.149(9), 1025–1032 (2013).
  • Ferrell PB Jr , McLeodHL. Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics9(10), 1543–1546 (2008).
  • Carbamazepine prescribing information to include recommendation of genetic test for patients with Asian ancestry (2007). www.fiercebiotech.com/biotech/press-release-carbamazepine-prescribing-information-to-include-recommendation-of-genetic
  • Shi YW , MinFL , ZhouDet al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology88(23), 2183–2191 (2017).
  • Shi YW , MinFL , QinBet al. Association between HLA and Stevens–Johnson syndrome induced by carbamazepine in southern Han Chinese: genetic markers besides B*1502? Basic Clin. Pharmacol. Toxicol. 111(1), 58–64 (2012).
  • Ikeda H , TakahashiY , YamazakiEet al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia51(2), 297–300 (2010).
  • Moon J , ParkHK , ChuKet al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia56(10), e161–167 (2015).
  • Azuma F , KashiwaseK. [HLA genotyping for molecular epidemiological analysis of humans]. Rinsho Byori61(11), 1026–1034 (2013).
  • Bunce M , O’NeillCM , BarnardoMCet al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens46(5), 355–367 (1995).
  • Fleischhauer K , ZinoE , BordignonC , BenazziE. Complete generic and extensive fine-specificity typing of the HLA-B locus by the PCR-SSOP method. Tissue Antigens46(4), 281–292 (1995).
  • He Y , TaoS , ZhangWet al. [Establishment of a polymerase chain reaction sequencing based typing method for HLA-DPB1 exons 2 and 3 and investigation of their polymorphisms]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi32(1), 40–43 (2015).
  • Bentley G , HiguchiR , HoglundBet al. High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens74(5), 393–403 (2009).
  • Han M , KangX , LiuZet al. Rapid and reliable genotyping of HLA-B*57:01 in Four Chinese populations using a single-tube duplex real-time polymerase chain reaction assay. AIDS Res. Hum. Retroviruses33(7), 711–717 (2017).
  • Zhang T , XiaoY , WangYet al. Single-tube multiplex real-time PCR assay for rapid and reliable detection of HLA-A*31:01 allele. Pharmacogenomics19(10), 837–846 (2018).
  • Wang H , KangX , ZhouSet al. Rapid and reliable screening of HLA-B*15:02 in four Chinese populations using single-tube multiplex real-time PCR assay. Pharmacogenomics18(9), 853–963 (2017).
  • Kang X , ChenR , HanMet al. Rapid and reliable genotyping of HLA-B*58:01 in four Chinese populations using a single-tube duplex real-time PCR assay. Pharmacogenomics17(1), 47–57 (2016).
  • Liu Z , ChenG , KangXet al. A multiplex allele-specific real-time polymerase chain reaction assay for HLA-B*13:01 genotyping in four Chinese populations. HLA88(4), 164–171 (2016).
  • Lin DF , YangYH , WangDPet al. [Detection of HLA-B*13:01 gene by dual allele-specific real-time polymerase chain reaction in patients with trichlorethylene-induced dermatitis]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases35(8), 589–591 (2017).
  • Nguyen DV , VidalC , ChiHCet al. A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions. Hla90(6), 335–342 (2017).
  • Newton CR , GrahamA , HeptinstallLEet al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res.17(7), 2503–2516 (1989).
  • Ellison G , DonaldE , McWalterGet al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J. Exp. Clin. Cancer Res.29, 132 (2010).
  • Qin L , ZhongW , ZhangL , LiLY , WangMZ. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin. Med. J.124(6), 887–891 (2011).
  • Ou GJ , WangJ , JiXet al. A study of HLA-B*15:02 in 9 different Chinese ethnics: implications for carbamazepine related SJS/TEN. HLA89(4), 225–229 (2017).
  • Yip VL , MarsonAG , JorgensenAL , PirmohamedM , AlfirevicA. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther.92(6), 757–765 (2012).
  • Sukasem C , ChaichanC , NakkrutTet al. Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J. Immunol. Res.2018, 2780272 (2018).
  • Alfirevic A , JorgensenAL , WilliamsonPR , ChadwickDW , ParkBK , PirmohamedM. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics7(6), 813–818 (2006).
  • Kaniwa N , SaitoY , AiharaMet al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics9(11), 1617–1622 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.